Identifying the mycobacterial genes controlling bacteriolysis in the macrophage cytoplasm
Project Number1R21AI181133-01
Contact PI/Project LeaderCHAMPION, PATRICIA A
Awardee OrganizationUNIVERSITY OF NOTRE DAME
Description
Abstract Text
PROJECT SUMMARY
Pathogenic mycobacteria damage the phagosome and interact with the macrophage cytoplasm. The mycobac-
terial factors that control bacteriolysis in the cytoplasm are unknown. The objective of this proposal is to define
the genes controlling mycobacterial bacteriolysis in the macrophage cytoplasm. The central hypothesis for this
application is that mycobacteria actively control bacteriolysis in the cytoplasm. To test this hypothesis, the fol-
lowing specific aims will be tested. The applicant has adapted an established reporter for cytoplasmic bacteriol-
ysis from Listeria monocytogenes for use with Mycobacterium. Under the first aim, the applicant proposes a
targeted approach to define the impact of known virulence factors on mycobacterial bacteriolysis. The objective
of Aim 1 is to define if known virulence pathways protect M. marinum from bacteriolysis. The applicant will test
the working hypothesis that known virulence pathways that modulate the inflammasome protect Mycobacterium
from bacteriolysis in the macrophage cytoplasm. M. marinum strains lacking specific virulence pathways will be
generated and bacteriolysis will be measured during macrophage infection. Under the second aim, the applicant
proposes an unbiased approach to identify genes required for cytoplasmic adaptation of mycobacterial patho-
gens. The objective of Aim 2 is to Identify genes the control mycobacterial bacteriolysis. The applicant will test
working hypothesis that several conserved pathways protect mycobacterial pathogens from bacteriolysis in the
cytoplasm. Two complementary genetic screens to identify molecular pathways controlling mycobacterial bacte-
riolysis in the cytoplasm during macrophage infection. The applicant expects that the successful completion of
Aim 1 will determine if known virulence pathways protect mycobacteria from bacteriolysis. The completion of
Aim 2 is expected to identify new pathways that promote mycobacterial survival in the cytoplasm. Completion of
the proposed aims will contribute an initial understanding of the mechanisms required for preventing mycobac-
terial bacteriolysis in the macrophage cytoplasm, moving the field in a new direction. This contribution will be
significant because it will identify a new molecular mechanism underlying mycobacterial pathogenesis. The ap-
plication is conceptually innovative because it focuses on mycobacterial determinants that protect mycobacteria
from bacteriolysis in the cytoplasm, which represents a shift in focus for the field. The experimental design is
innovative because it applies a novel indirect reporter of cytoplasmic bacteriolysis that has not previously been
used to study mycobacterial species.
Public Health Relevance Statement
Project Narrative
The proposed research is relevant to public health because the mycobacterial genes and
pathways that promote interactions with the host during infection are potential targets for the
development of new vaccines and therapeutics which would help to lessen tuberculosis. This
research is relevant to NIH’s mission because defining mycobacterial virulence that promote
survival during infection will contribute fundamental knowledge, which will be applicable to
tuberculosis prevention, diagnosis and treatment.
NIH Spending Category
No NIH Spending Category available.
Project Terms
BacteriaBacteriolysisCellsCessation of lifeCoupledCytoplasmDevelopmentDiagnosisEnvironmentExperimental DesignsGenesGenetic ScreeningGenus MycobacteriumGoalsGrowthImmune responseInfectionInfection ControlInflammasomeKnowledgeListeria monocytogenesMacrophageMeasuresMembraneMissionMolecularMycobacterium marinumPathogenesisPathogenicityPathway interactionsPhagocytesPhagosomesPreventionPublic HealthReporterResearchSystemTestingTimeTuberculosisUnited States National Institutes of HealthVirulenceVirulence Factorsactive controlcombatgenetic approachinnovationmutantmycobacterialnovelnovel therapeuticsnovel vaccinesoverexpressionpathogenpreventprotective pathway
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
824910376
UEI
FPU6XGFXMBE9
Project Start Date
17-May-2024
Project End Date
31-March-2026
Budget Start Date
17-May-2024
Budget End Date
31-March-2025
Project Funding Information for 2024
Total Funding
$234,750
Direct Costs
$150,000
Indirect Costs
$84,750
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$234,750
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21AI181133-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21AI181133-01
Patents
No Patents information available for 1R21AI181133-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21AI181133-01
Clinical Studies
No Clinical Studies information available for 1R21AI181133-01
News and More
Related News Releases
No news release information available for 1R21AI181133-01
History
No Historical information available for 1R21AI181133-01
Similar Projects
No Similar Projects information available for 1R21AI181133-01